Sir -We read with interest the paper of Vlasveld et al. (1993) , in which they report on the immunological aspects of constant infusion of low-dose recombinant interleukin 2 (IL-2) in melanoma and renal cell carcinoma patients, including the possible activation of T cells. When measured at weeks 0, 3 and later, they found that the number of T cells decreased, the CD4/CD8 ratios did not change, and there was no increased expression of CD25 and CD27, and no increased proliferation upon stimulation of peripheral blood lymphocytes with CD3 monoclonal antibody (MAb) with or without CD28 MAb. Therefore the authors concluded that prolonged low-dose IL-2 therapy does not induce T-cell activation.
We would like to comment that these observations might be influenced by the time points of analysis. In a longitudinal study during low-dose subcutaneous IL-2 therapy we demonstrated that IL-2 therapy does induce T-cell activation, as assessed by the increased expression of HLA-DR, during the first week of therapy, followed by a decrease in the number of T cells expressing the activated phenotype (Janssen et al., 1993) . Other investigators have reported T-cell activation during low-dose continuous intravenous infusion (Yoshino et al., 1991) .
It has been demonstrated that T cells sampled during IL-2 therapy become unresponsive to in vitro stimulation with CD3 MAb (Weil-Hillman et al., 1991; Janssen et al., 1993) . This might imply that IL-2 therapy induces T-cell anergy, causing the decrease in activated peripheral T cells during prolonged therapy. Another explanation could be the redistribution of activated and highly responding T cells to the tissues, leaving the low-responding T cells in the circulation. Taken together, these findings might explain why Vlasveld et al. did not find T-cell activation after 3 weeks of therapy.
There is mounting evidence that T cells play an important role in IL-2 therapy-induced anti-tumour activity (Parmiani, 1990; loannides & Whiteside, 1993; Maas et al., 1993) . It is therefore necessary to gain more insight in the ways in which T cells become activated during IL-2 therapy.
We conclude that low-dose IL-2 therapy can induce T-cell activation, although only temporarily in the first week of treatment. We suggest that researchers who are interested in T-cell activation during IL-2 therapy pay particular attention to the events induced during the early course of IL-2 therapy.
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